{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T15:26:34Z","timestamp":1779117994325,"version":"3.51.4"},"update-to":[{"DOI":"10.1002\/14651858.cd003189.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2008,10,8]],"date-time":"2008-10-08T00:00:00Z","timestamp":1223424000000}}],"reference-count":143,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd003189.pub4","type":"journal-article","created":{"date-parts":[[2008,10,8]],"date-time":"2008-10-08T21:07:07Z","timestamp":1223500027000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma"],"prefix":"10.1002","volume":"2010","author":[{"given":"Julia","family":"Bohlius","sequence":"first","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group - Department of Internal Medicine 1; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Herbst","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group - Department of Internal Medicine 1; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel","family":"Reiser","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Department of Internal Medicine 1; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Schwarzer","sequence":"additional","affiliation":[{"name":"German Cochrane Center; Department of Medical Biometry and Statistics; University Medical Center Stefan-Meier-Str. 26 Freiburg Germany D-79104"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Engert","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group - Department of Internal Medicine 1; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,10,8]]},"reference":[{"key":"10.1002\/14651858.CD003189.pub4-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<454::AID-CNCR28>3.0.CO;2-Q","article-title":"Short term treatment with Escherichia coli recombinant human granulocyte-macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease","volume":"88","author":"Aglietta","year":"2000","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0002|cit2","unstructured":"Personal communication in addition to Aglietta 2000"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3109\/10428199409051691","article-title":"Effect of granulocyte colony-stimulating factor in patients with diffuse large cell lymphoma treated with intensive chemotherapy","volume":"15","author":"Avil\u00e9s","year":"1994","journal-title":"Leukemia and Lymphoma"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0004|cit4","unstructured":"Personal communication in addition to Avil\u00e8s 1994"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0005|cit5","unstructured":"Bastion Y Bosly A Gisselbrecht C Reyes F Tilly H Herbrecht R A randomized double-blind phase III study of Filgrastim (recombinant human G-CSF) vs placebo during intensive induction chemotherapy in 55 to 59 year old patients (pts) with poor prognosis aggressive Non-Hodgkin's Lymphoma Blood 1993"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0006|cit6","unstructured":"Data on patients from the Bastion 1993 study who received ACVBP chemotherapy"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0007|cit7","unstructured":"Data on patients from the Bastion 1993 study who received VIMMM chemotherapy"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0008|cit8","unstructured":"Bj\u00f6rkholm M Osby E Hagberg H Kvaloy S Teerenhovi L Myhre J Randomized trial of r-metHu granulocyte colony-stimulating factor (G-CSF) as adjunct to CHOP or CNOP treatment of elderly patients with aggressive non-Hodgkin's lymphoma Blood 1999"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0009|cit9","unstructured":"Data on patients from the Bj\u00f6rkholm 1999 study who received CHOP chemotherapy"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0010|cit10","unstructured":"Data on patients from the Bj\u00f6rkholm 1999 study who received CNOP chemotherapy"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/sj.bjc.6602975","article-title":"A phase III trial comparing CHOP to PMitCEBO with or without G-CSf in patients aged 60 plus with aggressive non-Hodgkin\u00b4s lymphoma","volume":"94","author":"Burton","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0012|cit12","unstructured":"Data on patients from the Burton 2006 study who received CHOP"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0013|cit13","unstructured":"Data from patients in the Burton 2006 study who received PMitCEBO"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0014|cit14","unstructured":"Cunningham D Randomised trial of platinum based chemotherapy +\/-G-CSF in relapsed Non-Hodgkins and Hodgkins Lymphoma"},{"issue":"16","key":"10.1002\/14651858.CD003189.pub4-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1200\/JCO.2003.01.076","article-title":"CHOP compared to CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive Non-Hodgkin's Lymphoma","volume":"21","author":"Doorduijn","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0936-6555(05)80490-X","article-title":"Randomized multicentre trial of filgrastim as an adjunct to combination chemotherapy for Hodgkin's disease. West of Scotland Lymphoma Group","volume":"10","author":"Dunlop","year":"1998","journal-title":"Clinical Oncology (Royal College of Radiologists)"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0017|cit17","unstructured":"Data on patients from the Dunlop 1998 study who received MOPP chemotherapy"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0018|cit18","unstructured":"Personal communication in addition to Dunlop MOPP 1994"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0019|cit19","unstructured":"Data on patients from the Dunlop 1998 study who received MOPP\/EVAP chemotherapy"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0020|cit20","unstructured":"Personal communication in addition to Dunlop MOPP\/EVAP 1998"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/annonc\/5.suppl_2.S123","article-title":"Cytokine efficiency in the treatment of high-grade malignant non- Hodgkin's lymphomas: Results of a randomized double-blind placebo- controlled study with intensified COP-BLAM plus-or-minus sign rhGM- CSF.","volume":"5","author":"Engelhard","year":"1994","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s002770050330","article-title":"Randomized open label phase III trial of CEOP\/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP\/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor Therapy","volume":"75","author":"Fridrik","year":"1997","journal-title":"Annals of Hematology"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0023|cit23","unstructured":"Personal communication in addition to Fridrik 1997"},{"issue":"8","key":"10.1002\/14651858.CD003189.pub4-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood.V82.8.2329.2329","article-title":"Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant Non-Hodgkin's Lymphoma","volume":"82","author":"Gerhartz","year":"1993","journal-title":"Blood"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0025|cit25","article-title":"Recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to chemotherapy in aggressive non-Hodgkin's lymphomas","volume":"21, 6 Suppl (16","author":"Gerhartz","year":"1994","journal-title":"Seminars in Oncology"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3109\/10428199709114168","article-title":"Placebo-controlled phase III study of Lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte","volume":"25","author":"Gisselbrecht","year":"1997","journal-title":"Leukemia and Lymphoma"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0027|cit27","unstructured":"Personal communication in addition to Gisselbrecht 1997"},{"issue":"6","key":"10.1002\/14651858.CD003189.pub4-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1182\/blood.V80.6.1430.1430","article-title":"Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial","volume":"80","author":"Pettengell","year":"1992","journal-title":"Blood"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0029|cit29","article-title":"Economic analysis of Lenograstim in the correction of neutropenia following chemotherapy for non-Hodgkin's lymphoma","volume":"6, Suppl (2):36","author":"Sou\u00eatre","year":"1994","journal-title":"PharmacoEconomics"},{"issue":"11","key":"10.1002\/14651858.CD003189.pub4-BIB0030|cit30","first-page":"3974","article-title":"Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma","volume":"89","author":"Zinzani","year":"1997","journal-title":"Blood"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0031|cit31","unstructured":"Personal communication in addition to Zinzani 1997"},{"issue":"1","key":"10.1002\/14651858.CD003189.pub4-BIB0032|cit32","first-page":"33","article-title":"Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients","volume":"94","author":"Zinzani","year":"1999","journal-title":"Blood"},{"issue":"10","key":"10.1002\/14651858.CD003189.pub4-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1182\/blood-2002-10-3238","article-title":"CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial","volume":"101","author":"\u00d6sby","year":"2003","journal-title":"Blood"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0034|cit34","article-title":"Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphoma","volume":"25, 2 suppl (4)","author":"Adde","year":"1998","journal-title":"Seminars in Oncology"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0002-9343(96)90006-6","article-title":"Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) in cancer patients with fever and neutropenia","volume":"100","author":"Anaissie","year":"1996","journal-title":"The American Journal of Medicine"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1016\/0959-8049(95)00195-6","article-title":"Recombinant human granulocyte-macrophage colony-stimulating factor after combined chemotherapy in high-grade non-Hodgkin's lymphoma - a randomised pilot study","volume":"31A","author":"Bergmann","year":"1995","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3109\/10428199609054787","article-title":"The treatment of elderly patients with aggressive non-Hodgkin's lymphomas: feasibility and efficacy of an intensive multidrug regimen.","volume":"22","author":"Bertini","year":"1996","journal-title":"Leukemia and Lymphoma"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0038|cit38","article-title":"Role of granulocyte-macrophage colony-stimulating factor as adjuvant treatment in neutropenic patients with bacterial and fungal infection","volume":"13 Suppl (2):18","author":"Bodey","year":"1994","journal-title":"European journal of clinical microbiology & infectious diseases"},{"issue":"2","key":"10.1002\/14651858.CD003189.pub4-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0145-2126(93)90063-Q","article-title":"Intervention treatment of established neutropenia with human recombinant granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in patients undergoing cancer chemotherapy","volume":"17","author":"Gerhartz","year":"1993","journal-title":"Leukemia Research"},{"issue":"5","key":"10.1002\/14651858.CD003189.pub4-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1200\/JCO.1990.8.5.768","article-title":"Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma","volume":"8","author":"Gianni","year":"1990","journal-title":"Jounral of Clinical Oncology"},{"issue":"10","key":"10.1002\/14651858.CD003189.pub4-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1182\/blood.V94.10.3307.422k11_3307_3314","article-title":"A phase II trial of 200% ProMACE-CytaBOM in patients with previously untreated aggressive lymphomas: Analysis of response, toxicity, and dose intensity","volume":"94","author":"Gordon","year":"1999","journal-title":"Blood"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0042|cit42","unstructured":"Gregory S Goh YT Fuerst T O'Brien T Giles FJ Fludarabine, cyclophosphamide and GM-CSF is effective in chronic lymphocytic leukemia and low grade non Hodgkins lymphoma Blood 1998"},{"issue":"5","key":"10.1002\/14651858.CD003189.pub4-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3109\/02841869709001303","article-title":"G-CSF (filgrastim) as an adjunct to MOPP\/ABVD therapy in Hodgkin's disease","volume":"36","author":"Gustavsson","year":"1997","journal-title":"Acta Oncologica"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3109\/10428199509112204","article-title":"Short-term rhG-CSF priming before chemotherapy does mobilize blood progenitors but does not prevent chemotherapy induced myelotoxicity: a randomized study of patients with non-Hodgkin's lymphomas","volume":"19","author":"Hansen","year":"1995","journal-title":"Leukemia and Lymphoma"},{"issue":"25","key":"10.1002\/14651858.CD003189.pub4-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1056\/NEJM199706193362502","article-title":"Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia","volume":"336","author":"Hartmann","year":"1997","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0046|cit46","first-page":"14","article-title":"Sequential studies on the role of mitoxantrone, high-dose cytarabine, and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of refractory non-Hodgkin's lymphoma","volume":"17","author":"Ho","year":"1990","journal-title":"Seminars in Oncology"},{"issue":"3","key":"10.1002\/14651858.CD003189.pub4-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1200\/JCO.1992.10.3.390","article-title":"Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with Hodgkin's disease: A Phase I\/II Study","volume":"10","author":"Hovgaard","year":"1992","journal-title":"Journal of Clinical Oncology"},{"issue":"3-4","key":"10.1002\/14651858.CD003189.pub4-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3109\/10428199309087000","article-title":"Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) after chemotherapy in patients with non-Hodgkin's lymphoma; a placebo-controlled double blind phase III trial","volume":"11","author":"Kaku","year":"1993","journal-title":"Leukemia and Lymphoma"},{"issue":"1","key":"10.1002\/14651858.CD003189.pub4-BIB0049|cit49","first-page":"51","article-title":"Outline of clinical studies on recombinant human granulocyte colony stimulating factor (KRN 8601) in Japan","volume":"16","author":"Kaneko","year":"1991","journal-title":"Tokai Journal of Experimental & Clinical Medicine"},{"issue":"6","key":"10.1002\/14651858.CD003189.pub4-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.1991.9.6.929","article-title":"Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial","volume":"9","author":"Kaplan","year":"1991","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD003189.pub4-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/sj.bmt.1701434","article-title":"Effect of topical oral G-CSF on oral mucositis: a randomised placebo-controlled trial","volume":"22","author":"Karthaus","year":"1998","journal-title":"Bone Marrow Transplantation"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0052|cit52","article-title":"GM-CSF: clinical trials in non-Hodgkin's lymphoma patients with chemotherapy induced leucopenia","volume":"5 Suppl (1): 11","author":"Liberati","year":"1991","journal-title":"Leukemia"},{"issue":"2","key":"10.1002\/14651858.CD003189.pub4-BIB0053|cit53","first-page":"99","article-title":"Factor estimulante de colonias de granulocitos en el tratamiento de neutropenia febril","volume":"136","author":"Lopez-Hernandez","year":"2000","journal-title":"Gaceta medica de Mexico"},{"issue":"3","key":"10.1002\/14651858.CD003189.pub4-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1200\/JCO.1996.14.3.925","article-title":"Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen","volume":"14","author":"Magrath","year":"1996","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0055|cit55","first-page":"492","article-title":"Filgrastim in patients with chemotherapy-induced febrile neutropenia","volume":"121","author":"Maher","year":"1994","journal-title":"American College of Physicians"},{"issue":"10","key":"10.1002\/14651858.CD003189.pub4-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/0959-8049(93)90011-4","article-title":"Granulocyte colony-stimulating factor (G-CSF) with or without a quinolone in the prevention of infection in cancer patients","volume":"29A","author":"Maiche","year":"1993","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/030089169508100204","article-title":"Role of granulocyte colony-stimulating factor in relapsed\/resistant intermediate and high-grade non-Hodgkin's lymphoma patients treated with the E-SHAP regimen","volume":"81","author":"Mangiagalli","year":"1995","journal-title":"Tumori"},{"issue":"11","key":"10.1002\/14651858.CD003189.pub4-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/jnci\/87.11.803","article-title":"Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors","volume":"87","author":"Mayordomo","year":"1995","journal-title":"Journal of the National Cancer Institute"},{"issue":"2","key":"10.1002\/14651858.CD003189.pub4-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1200\/JCO.1997.15.2.660","article-title":"Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma","volume":"15","author":"Moreau","year":"1997","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0060|cit60","first-page":"1069","article-title":"Protective effect of partially purified human urinary colony-stimulating factor on granulocytopenia after antitumor chemotherapy","volume":"14","author":"Motoyoshi","year":"1986","journal-title":"Experimental Hematology"},{"issue":"6","key":"10.1002\/14651858.CD003189.pub4-BIB0061|cit61","first-page":"410","article-title":"Usefulness of COP-BLAM Therapy with concomitant G-CSF in elderly patients with non-Hodgkin's lymphoma in comparison with patients not given G-CSF","volume":"32","author":"Niitsu","year":"1995","journal-title":"Japanese Journal of Geriatrics"},{"issue":"3","key":"10.1002\/14651858.CD003189.pub4-BIB0062|cit62","first-page":"365","article-title":"[A phase III study of KRN 8601 (rhG-CSF) on neutropenia induced by chemotherapy for malignant lymphoma--a multi-institutional placebo controlled double-blind comparative study]","volume":"17","author":"Ogawa","year":"1990","journal-title":"Gan-To-Kagaku-Ryoho. Cancer & chemotherapy"},{"issue":"1","key":"10.1002\/14651858.CD003189.pub4-BIB0063|cit63","first-page":"44","article-title":"MOPP\/ABVD\/CAD chemotherapy with and without recombinant human granulocyte-macrophage colony stimulating factor in untreated, unfavorable prognosis Hodgkin's disease","volume":"78","author":"Riccardi","year":"1993","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1016\/0959-8049(95)00197-2","article-title":"A single-blind, randomised, vehicle-controlled dose-finding study of recombinant human granulocyte colony-stimulating factor (lenograstim) in patients undergoing chemotherapy for solid cancers and lymphoma","volume":"31A","author":"Seymour","year":"1995","journal-title":"European Journal of Cancer"},{"issue":"5","key":"10.1002\/14651858.CD003189.pub4-BIB0065|cit65","first-page":"356","article-title":"Clinical study of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced leukopenia","volume":"16","author":"Shi","year":"1994","journal-title":"Chung Hua Chung Liu Tsa Chih"},{"issue":"4","key":"10.1002\/14651858.CD003189.pub4-BIB0066|cit66","first-page":"252","article-title":"Clinical study of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on leukopenia induced by chemotherapy with CHOP and CAF regimen in cancer patients","volume":"23","author":"Shi","year":"1996","journal-title":"Chinese Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD003189.pub4-BIB0067|cit67","first-page":"115","article-title":"Clinical evalutaion of rhG-CSF in patients with neutropenia induced by chemotherapy for multiple myeloma","volume":"41","author":"Togawa","year":"2000","journal-title":"Rinsho Ketsueki. The Japanese Journal of Clinical Hematology"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0068|cit68","unstructured":"Phase III randomized double-blind study of intensive chemotherapy with ARA-C\/CACP\/VP-16 plus GM-CSF vs placebo in patients with relapsing or refractory intermediate- and high-grade non-Hodgkin's lymphoma (summary last modified 11\/90) http:\/\/cancernet.nci.nih.gov\/cgi-bin\/"},{"issue":"2","key":"10.1002\/14651858.CD003189.pub4-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.1996.14.2.619","article-title":"Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia","volume":"14","author":"Vellenga","year":"1996","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD003189.pub4-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1200\/JCO.1998.16.7.2345","article-title":"Phase II and dose-escalation with or without granulocyte colony-stimulating factor study of 9-aminocamptothecin in relapsed and refractory lymphomas","volume":"16","author":"Wilson","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/(SICI)1096-8652(199604)51:4<289::AID-AJH7>3.0.CO;2-S","article-title":"Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating-factor support for dose-intensive cyclophosphamide, etoposide, and cisplatin","volume":"51","author":"Yau","year":"1996","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0072|cit72","first-page":"81","article-title":"Effect of granulocyte-colony stimulating factor on empiric therapy with flomoxef sodium and tobramycin in febrile neutropenic patients with hematological malignancies. Kan-etsu Hematological Disease and Infection Study Group.","volume":"69","author":"Yoshida","year":"1999","journal-title":"International Journal of Hematology"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0073|cit73","article-title":"Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy","volume":"5 Suppl (2):S12","author":"Zagonel","year":"1994","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0074|cit74","unstructured":"Blay JY Elypse 2 personal communication"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0075|cit75","unstructured":"Cunningham D A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma MREC\/98\/2\/52"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0076|cit76","first-page":"77","article-title":"Neutrophil recovery time and adverse side effects in acute leukemia patients treated with intensive chemotherapy and concomitant G or GM-CSF","volume":"51","author":"Alvarado Ibarra","year":"1999","journal-title":"La Revista de Investigaci\u00f3n Cl\u00ednica"},{"issue":"14","key":"10.1002\/14651858.CD003189.pub4-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJM199304083281409","article-title":"The treatment of non-Hodgkin's lymphoma","volume":"328","author":"Armitage","year":"1993","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD003189.pub4-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1200\/JCO.1994.12.11.2471","article-title":"American Society of Clinical Oncology Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines","volume":"12","author":"No authors","year":"1994","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD003189.pub4-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1200\/JCO.1996.14.6.1957","article-title":"Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based Clinical Practice Guidelines","volume":"14","author":"No authors","year":"1996","journal-title":"Journal of Clinical Oncology"},{"issue":"20","key":"10.1002\/14651858.CD003189.pub4-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1200\/JCO.2000.18.20.3558","article-title":"2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines","volume":"18","author":"Ozer","year":"2000","journal-title":"Journal of Clinical Oncology"},{"issue":"19","key":"10.1002\/14651858.CD003189.pub4-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","article-title":"2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1002\/14651858.CD003189.pub4-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1055\/s-0038-1650276","article-title":"Thrombosis in cancer patients treated with hematopoietic growth factors - a meta-analysis. On behalf of the Subcommittee on Haemaostasis and Malignancy of the Scientific and Standardization Committee of the ISTH","volume":"75","author":"Barbui","year":"1996","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0083|cit83","unstructured":"Bennett CL Stinson TJ Bhoopalam N Marriott M Panganiban J Kozloff MF A double-Blind, randomized trial of toxicity, resource use and costs for filgrastim and sargramostim Conference Proceedings of the American Society of Hematology 2000 abstract no 1712"},{"issue":"1-2","key":"10.1002\/14651858.CD003189.pub4-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3109\/10428190009057629","article-title":"Cost analysis of adjunct colony stimulating factors for acute leukemia: can they improve clinical decision making","volume":"37","author":"Bennett","year":"2000","journal-title":"Leukemia and Lymphoma"},{"issue":"6","key":"10.1002\/14651858.CD003189.pub4-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3109\/07357909809115775","article-title":"A comparison of efficacy of sargramostim (yeast-derived rhuGM-CSF) and filgrastim (bacteria-derived rhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression","volume":"16","author":"Beveridge","year":"1998","journal-title":"Cancer Investigation"},{"issue":"2","key":"10.1002\/14651858.CD003189.pub4-BIB0086|cit86","first-page":"63","article-title":"Neutropenic complications in advanced-stage non-Hodgkin lymphoma: implications for the use of prophylactic recombinant human granulocyte-colony stimulating factor (G-CSF)","volume":"21","author":"Bobey","year":"1998","journal-title":"Clinical and Investigative Medicine - Medicine Clinique et Experimentale"},{"issue":"2","key":"10.1002\/14651858.CD003189.pub4-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"328","DOI":"10.7326\/0003-4819-64-2-328","article-title":"Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia","volume":"64","author":"Bodey","year":"1966","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0088|cit88","article-title":"Infection in cancer patients","volume":"81 Suppl (1A):","author":"Bodey","year":"1986","journal-title":"The American Journal of Medicine"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0089|cit89","article-title":"Infection risk and cancer chemotherapy: the impact of the chemotherapeutic regimen in patients with lymphoma and solid tissue malignancies","volume":"41 Suppl (D):1-","author":"Bow","year":"1998","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"1","key":"10.1002\/14651858.CD003189.pub4-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/bjc.1988.163","article-title":"In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients","volume":"58","author":"Bronchud","year":"1988","journal-title":"British Journal of Cancer"},{"issue":"10","key":"10.1002\/14651858.CD003189.pub4-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1200\/JCO.1995.13.10.2629","article-title":"Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity","volume":"13","author":"Bui","year":"1995","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD003189.pub4-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.1995.13.7.1564","article-title":"Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer","volume":"13","author":"Chevallier","year":"1995","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD003189.pub4-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199107183250305","article-title":"Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung-cancer","volume":"325","author":"Crawford","year":"1991","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD003189.pub4-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000227575","article-title":"Dose intensity of standard adjuvant CMF with granulocyte colony-stimulating factor for premenopausal patients with node-positive breast cancer","volume":"53","author":"Graaf","year":"1996","journal-title":"Oncology"},{"issue":"5","key":"10.1002\/14651858.CD003189.pub4-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1182\/blood.V79.5.1359.1359","article-title":"Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T-cell-depleted bone marrow transplantation","volume":"79","author":"Witte","year":"1992","journal-title":"Blood"},{"issue":"1B","key":"10.1002\/14651858.CD003189.pub4-BIB0096|cit96","first-page":"489","article-title":"Shortened time to recovery from chemotherapy induced neutropenia in pediatric patients with high dose combined cytokines","volume":"18","author":"Deb","year":"1998","journal-title":"Anticancer Research"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0097|cit97","first-page":"285","article-title":"Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis","volume-title":"Systematic Reviews in Health Care. Meta-analysis in context","author":"Deeks","year":"2001"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0098|cit98","first-page":"5155","article-title":"Human hematopoietic growth factors: Old lessons and new perspectives","volume":"20","author":"Dempke","year":"2000","journal-title":"Anticancer Research"},{"issue":"22","key":"10.1002\/14651858.CD003189.pub4-BIB0099|cit99","first-page":"5810","article-title":"The chemotherapy of lymphomas: looking back, moving forward. The Richard and Hinda Rosenthal Foundation Award Lecture","volume":"47","author":"DeVita","year":"1987","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/bmj.309.6964.1286","article-title":"Identifying relevant studies for systematic reviews","volume":"309","author":"Dickersin","year":"1994","journal-title":"British Medical Journal"},{"issue":"24","key":"10.1002\/14651858.CD003189.pub4-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease","volume":"348","author":"Diehl","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"7109","key":"10.1002\/14651858.CD003189.pub4-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0103|cit103","first-page":"180","article-title":"Malignant Lymphoma","volume-title":"Innere Medizin","volume":"1","author":"Engert","year":"1994"},{"issue":"15","key":"10.1002\/14651858.CD003189.pub4-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.ejca.2006.05.002","article-title":"EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours","volume":"42","author":"Aapro","year":"2006","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0105|cit105","first-page":"833","article-title":"Maligne Diseases of lymphatic cells","volume-title":"Harrisons Innere Medizin","volume":"1","author":"Freedman","year":"1999"},{"issue":"2","key":"10.1002\/14651858.CD003189.pub4-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/bjc.1997.50","article-title":"CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer","volume":"75","author":"Fukuoka","year":"1997","journal-title":"British Journal of Cancer"},{"issue":"10","key":"10.1002\/14651858.CD003189.pub4-BIB0107|cit107","first-page":"923","article-title":"Quantitative model for multiple levels of drug resistance in clinical tumours","volume":"67","author":"Goldie","year":"1983","journal-title":"Cancer Treatment Reports"},{"issue":"7","key":"10.1002\/14651858.CD003189.pub4-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/sj.bjc.6601708","article-title":"Are prophylactic haematopoietic growth factors of value in the management of patients with aggressive non-Hodgkin's lymphoma?","volume":"90","author":"Hackshaw","year":"2004","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0109|cit109","first-page":"1009","article-title":"Lymphoproliferative diseases","volume-title":"Innere Medizin","volume":"1","author":"Herrmann","year":"1998"},{"issue":"11","key":"10.1002\/14651858.CD003189.pub4-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1200\/JCO.1984.2.11.1281","article-title":"The importance of dose intensity in chemotherapy of metastatic breast cancer","volume":"2","author":"Hryniuk","year":"1984","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD003189.pub4-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1200\/JCO.1986.4.8.1162","article-title":"Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer","volume":"4","author":"Hryniuk","year":"1986","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD003189.pub4-BIB0112|cit112","first-page":"65","article-title":"Average relative dose intensity and the impact on design of clinical trials","volume":"14","author":"Hryniuk","year":"1987","journal-title":"Seminars in Oncology"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0113|cit113","first-page":"1905","article-title":"Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group","volume":"18","author":"ICH Harmonised Tripartite","year":"1999","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: Is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"issue":"16","key":"10.1002\/14651858.CD003189.pub4-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","article-title":"The multinational association for supportive care in cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients","volume":"18","author":"Klastersky","year":"2000","journal-title":"Journal of Clinical Oncology"},{"issue":"21","key":"10.1002\/14651858.CD003189.pub4-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","article-title":"Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. [Review] [81 refs]","volume":"25","author":"Kuderer","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD003189.pub4-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/oxfordjournals.annonc.a058619","article-title":"Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to LNH-87 protocol","volume":"4","author":"Lepage","year":"1993","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1002\/14651858.CD003189.pub4-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1172\/JCI112705","article-title":"Recombinant human granulocyte-macrophage colony stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surfae receptor expression, and survival","volume":"78","author":"Lopez","year":"1986","journal-title":"Journal of Clinical Investigation"},{"issue":"6","key":"10.1002\/14651858.CD003189.pub4-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3109\/08880019509030769","article-title":"Efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granuloyte-macrophage colony-stimulating factor in neutropenic children with malignancies","volume":"12","author":"Lydaki","year":"1995","journal-title":"Pediatric Hematology and Oncology"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0120|cit120","article-title":"A cost analysis of hematopoietic colony-stimulating factors","volume":"9 Suppl (11):85","author":"Lyman","year":"1995","journal-title":"Oncology (Huntingt)"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/00001622-199807000-00003","article-title":"Economic impact of granulopoiesis stimulating agents on the management of febrile neutropenia","volume":"10","author":"Lyman","year":"1998","journal-title":"Current Opinion in Oncology"},{"issue":"7 Pt 2","key":"10.1002\/14651858.CD003189.pub4-BIB0122|cit122","first-page":"104","article-title":"A predictive model for neutropenia associated with cancer chemotherapy","volume":"20","author":"Lyman","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0002-9343(02)01036-7","article-title":"Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: A meta-analysis","volume":"112","author":"Lyman","year":"2002","journal-title":"The American Journal of Medicine"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0124|cit124","unstructured":"Magrath I Adde M Shad A Venzon D Seibel N Neeley J Relative efficacy of G-and GM-CSF in ameliorating toxicity in an intensive treatment protocol for advanced, diffuse B cell NHLs, predominantly small noncleaved cell lymphomas Abstracts of the American Society of Hematology 1997 abstract no 847"},{"issue":"1","key":"10.1002\/14651858.CD003189.pub4-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0140-6736(88)91475-4","article-title":"Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy","volume":"26","author":"Morstyn","year":"1988","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parma","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1182\/blood.V82.7.2239.2239","article-title":"Transplantation potential of hematopoietic cells released into the circulation during routine chemotherapy for non-Hodgkin's lymphoma [see comments].","volume":"82","author":"Pettengell","year":"1993","journal-title":"Blood"},{"issue":"9","key":"10.1002\/14651858.CD003189.pub4-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1185\/030079907X219599","article-title":"Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials","volume":"23","author":"Pinto","year":"2007","journal-title":"Current Medical Research & Opinion"},{"issue":"3","key":"10.1002\/14651858.CD003189.pub4-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD003189.pub4-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood-2003-06-2094","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD003189.pub4-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3816\/CLM.2005.n.023","article-title":"The combination of fludarabine, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor in the treatment of patients with relapsed chronic lymphocytic leukemia and low-grade Non-Hodgkin's lymphoma","volume":"6","author":"Rao","year":"2005","journal-title":"Clinical Lymphoma"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0132|cit132","first-page":"51","article-title":"Pharmacology of filgrastim (r-metHuG-CSF)","volume-title":"Filgastim (r-metHuG-CSF) in Clinical Practice","author":"Roskos","year":"1998"},{"issue":"4","key":"10.1002\/14651858.CD003189.pub4-BIB0133|cit133","first-page":"179","article-title":"Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer","volume":"2","author":"Rusthoven","year":"1998","journal-title":"Cancer Prevention and Control"},{"issue":"1","key":"10.1002\/14651858.CD003189.pub4-BIB0134|cit134","first-page":"43","article-title":"Dose intensity versus total dose of chemotherapy: an experimental basis","volume":"1","author":"Skipper","year":"1990","journal-title":"Important Advances in Oncology"},{"issue":"6","key":"10.1002\/14651858.CD003189.pub4-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"400","DOI":"10.7326\/0003-4819-147-6-200709180-00010","article-title":"Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection","volume":"147","author":"Sung","year":"2007","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1002\/14651858.CD003189.pub4-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.1992.10.2.316","article-title":"Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule","volume":"10","author":"Talcott","year":"1992","journal-title":"Journal of Clinical Oncology"},{"issue":"31","key":"10.1002\/14651858.CD003189.pub4-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"7974","DOI":"10.1200\/JCO.2004.00.7955","article-title":"Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study","volume":"23","author":"Timmer-Bonte","year":"2005","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD003189.pub4-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0959-8049(93)90376-Q","article-title":"Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy","volume":"29A","author":"Trillet-Lenoir","year":"1993","journal-title":"European Journal of Cancer"},{"issue":"12","key":"10.1002\/14651858.CD003189.pub4-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S0895-4356(98)00131-0","article-title":"The delphi list: A criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by delphi consensus","volume":"51","author":"Verhagen","year":"1998","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2 SUPPL. 1","key":"10.1002\/14651858.CD003189.pub4-BIB0140|cit140","first-page":"58","article-title":"Pegfilgrastim nearly abrogates occurrence of neutropenic events early in the course of chemotherapy: Results of a phase III, randomized, double-blind, placebo-controlled study of patients with breast cancer receiving docetaxel","volume":"3","author":"Vogel","year":"2005","journal-title":"The Journal of Supportive Oncology"},{"issue":"3","key":"10.1002\/14651858.CD003189.pub4-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1200\/JCO.1995.13.3.652","article-title":"Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer","volume":"13","author":"Woll","year":"1995","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD003189.pub4-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/1097-0142(19901101)66:9<1904::AID-CNCR2820660908>3.0.CO;2-V","article-title":"Effect of granulocyte colony-stimulating factor on neutropenia due to chemotherapy for non-Hodgkin's lymphoma","volume":"66","author":"Yoshida","year":"1990","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD003189.pub4-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1046\/j.1365-2141.2003.04450.x","article-title":"Impact of granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF in patients with malignant lymphoma: a systematic review","volume":"122","author":"Bohlius","year":"2003","journal-title":"British Journal of Haematology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD003189.pub4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T18:04:13Z","timestamp":1777313053000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD003189.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Haematology Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2008,10,8]]},"references-count":143,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2010,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003189.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,8]]}}}